FindTrial
Sign In

A prospective observational study of the efficacy and safety of CPT-11 based regimens (CPT-11+platinum analogues) for UGT1A1 genotype guided patients

A prospective observational study of the efficacy and safety of CPT-11 based regimens (CPT-11+platinum analogues) for UGT1A1 genotype guided patients

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080220914
Enrollment
1000
Registered
2009-11-10
Start date
2009-11-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer and gastric cancer (inoperable or recurrent)

Interventions

investigational material(s) Generic name etc : Irinotecan hydrochloride INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and

Sponsors

DAIICHI SANKYO COMPANY, LIMITED
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer and gastric cancer 2. Patients to receiving CPT-11 plus platinum anolaogues regimens Age requirement none

Exclusion criteria

Exclusion criteria: 1. Contraindications of CPT-11 2. ECOG PS 3-4

Design outcomes

Primary

MeasureTime frame
Safety None—

Secondary

MeasureTime frame
Efficacy None—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026